Literature DB >> 28831507

[Can 12- instead of 4‑weekly zoledronic acid administration reduce skeletal events in patients with bone metastases?]

Dirk Rades1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28831507     DOI： 10.1007/s00066-017-1191-0

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  10 in total

1.  Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression.

Authors:  Dirk Rades; Marisa Lange; Theo Veninga; Lukas J A Stalpers; Amira Bajrovic; Irenaeus A Adamietz; Volker Rudat; Steven E Schild
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-06       Impact factor: 7.038

2.  American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

Authors:  Catherine H Van Poznak; Sarah Temin; Gary C Yee; Nora A Janjan; William E Barlow; J Sybil Biermann; Linda D Bosserman; Cindy Geoghegan; Bruce E Hillner; Richard L Theriault; Dan S Zuckerman; Jamie H Von Roenn
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

3.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Authors:  David H Henry; Luis Costa; Francois Goldwasser; Vera Hirsh; Vania Hungria; Jana Prausova; Giorgio Vittorio Scagliotti; Harm Sleeboom; Andrew Spencer; Saroj Vadhan-Raj; Roger von Moos; Wolfgang Willenbacher; Penella J Woll; Jianming Wang; Qi Jiang; Susie Jun; Roger Dansey; Howard Yeh
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

4.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

5.  Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.

Authors:  Andrew L Himelstein; Jared C Foster; James L Khatcheressian; John D Roberts; Drew K Seisler; Paul J Novotny; Rui Qin; Ronald S Go; Stephen S Grubbs; Tracey O'Connor; Mario R Velasco; Douglas Weckstein; Ann O'Mara; Charles L Loprinzi; Charles L Shapiro
Journal:  JAMA       Date:  2017-01-03       Impact factor: 56.272

6.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Authors:  Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

7.  Impact of zoledronic acid on control of metastatic spinal cord compression.

Authors:  D Rades; S G Hakim; A Bajrovic; J H Karstens; T Veninga; V Rudat; S E Schild
Journal:  Strahlenther Onkol       Date:  2012-08-19       Impact factor: 3.621

8.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Ming Zheng
Journal:  J Natl Cancer Inst       Date:  2004-06-02       Impact factor: 13.506

9.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

10.  Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

Authors:  Matthew R Smith; Susan Halabi; Charles J Ryan; Arif Hussain; Nicholas Vogelzang; Walter Stadler; Ralph J Hauke; J Paul Monk; Philip Saylor; Nirmala Bhoopalam; Fred Saad; Ben Sanford; W Kevin Kelly; Michael Morris; Eric J Small
Journal:  J Clin Oncol       Date:  2014-03-03       Impact factor: 44.544
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.